BRYAN/COLLEGE STATION, Texas, April 25, 2011 /PRNewswire/ —
Caliber Biotherapeutics, a fully-integrated biopharmaceutical
company, announced the opening of the world’s largest plant-made
pharmaceutical manufacturing facility in Bryan, Texas, with the
capability of producing 10-100 million doses of infectious vaccines
per month, and hundreds of thousands of doses of protein
biotherapeutics such as monoclonal antibodies.
In addition to its plant-based facility, Caliber will also
develop a proprietary product pipeline for cancer and infectious
diseases utilizing cell- and microbial-based production systems.
The end result will be new, more effective and affordable vaccines
and biotherapeutics for patients – delivered in a time frame
in which they are needed.
Led by physician-scientist and biodefense expert, Brett Giroir,
M.D., and Barry Holtz, Ph.D., an internationally recognized pioneer
in plant-made pharmaceuticals, Caliber Biotherapeutics represents a
fundamentally different approach to vaccine and drug
development.
“With plant-based systems, we have an unprecedented level of
flexibility and scalability,” said Dr. Holtz, Caliber’s Chief
Scientific Officer. “This enables simultaneous production of
multiple proteins and rapid change-overs from one product to
another in order to meet patients’ needs and respond to emerging
infectious diseases and bioterror threats.”
“The Caliber platform is designed to be uniquely agile and
responsive, enabling us to accelerate development of products with
improved efficacy, reduced cost and enhanced safety,” said Dr.
Giroir, Chief Medical Officer. “Our goal is to make a rapid,
meaningful impact on patients with unmet medical needs, both in the
United States as well as in lesser developed countries with
profound public health challenges.”
In the coming months, Caliber will be announcing new major
strategic alliances and its priorities for product development.
About Caliber
‘/>”/>
